Our center activities have started in 1991 in order to help patients in need and augment new data to reach new aspects of therapeutic trials. Also it is one of the greatest bone marrow transplantation centers in the world and is the second center in the world transplanting thalassemic patients. Also this center is doing scientific activities, so that it has presented over 250 assays in international congresses and also more than 150 thesis has been performed. Since the year 1991, when bone marrow transplantation was performed for the first time on three patients with Acute Myelogenous Leukemia(AML), Acute Lymphoblastic Leukemia (ALL) and Ewing Sarcoma, 2376 Hematopoietic Stem Cell Transplantation (HSCT) have been performed in patient with different diseases .There are 1538 cases that have received allogeneic HSCT and 703 cases that have received autologous HSCT. The first peripheral blood HSCT was performed in 1997 and since then, 1840 patients were done with this method. The first cord blood HSCT was performed in 1998 and since then there are 14 patients received HSCT from cord blood. We had 121 patients with Cellular Therapy (a technology that relies on replacing diseased or dysfunctional cells with healthy, functioning ones) for post MI, Thalassemia major, Multiple Sclerosis, Cirrhosis, Head of Femour Necrosis and Renal Cell Carcinoma. Recently, new methods have been used like low intensity conditioning regimen (non myeloablative) and Donor Lymphocyte Infusion (DLI).This center is the member of the International Blood and Marrow Transplantation Registry (IBMTR) and European group of Blood and Marrow Transplantation (EBMTR). So that gives help to researchers for a better understanding of transplantation and invent new therapeutic methods. Our center is the member of Asian Pacific Cancer Center (APCC) and also we are collaborating with Blood and Cancer Associations such as American Society of Hematology (ASH), International Society of Hematology (ISH), and European School of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), and other centers. The plans and aims include protraction of cytogenetice and molecular biological diagnostic tests, invention of a cord blood bank and develop the research activities in these fields.